Artificial intelligence in impurity prediction: current landscape, challenges, and future directions

Clinical Snapshot

Key Findings

• P Value: Not reported

• Effect Size: Not applicable — no quantitative pooled effect sizes reported; individual model performance metrics from cited studies are discussed qualitatively without aggregation

• Primary Outcome: Narrative synthesis of AI and machine learning methodologies for pharmaceutical impurity prediction, including QSAR models, graph neural networks, transformer-based architectures, and generative frameworks

• Nnt Or Sensitivity: Not applicable in traditional clinical sense; the review discusses model performance characteristics (accuracy, predictive validity) qualitatively but does not report pooled sensitivity, specificity, AUC, or other diagnostic performance metrics across studies

• Confidence Interval: Not reported — no meta-analytic synthesis performed

Clinical Application

Implementation of AI-based impurity prediction tools in pharmaceutical development pipelines is technically feasible at large pharmaceutical companies with dedicated computational chemistry resources. However, significant barriers remain: data availability and curation requirements are substantial; model validation for regulatory submission is not yet standardised; and smaller manufacturers or generic drug producers may lack the computational infrastructure. The review acknowledges these barriers but does not provide implementation roadmaps or cost-effectiveness data. In Australia, pharmaceutical impurity assessment is governed by TGA guidelines aligned with ICH Q3A (impurities in new drug substances), Q3B (impurities in new drug products), and ICH M7 (assessment and control of DNA reactive mutagenic impurities). AI-based impurity prediction tools, if validated, could support TGA submissions by enabling more comprehensive impurity profiling earlier in development. The TGA has not yet issued specific guidance on the use of computational AI models for impurity prediction in regulatory submissions, though ICH M7 already permits use of (Q)SAR tools for mutagenicity assessment of impurities. PBS implications are indirect — faster, more cost-effective impurity characterisation could reduce development costs and potentially support earlier generic entry. RACGP guidelines do not directly address pharmaceutical manufacturing impurity assessment. Australian generic manufacturers and the TGA's adoption of ICH guidelines make this topic relevant to local regulatory practice, though the review does not specifically address Australian or Asia-Pacific regulatory contexts. Pharmaceutical scientists, medicinal chemists, and regulatory affairs professionals involved in drug development, impurity profiling, and quality control. Indirectly relevant to clinical pharmacologists and toxicologists assessing drug safety profiles.

Abstract

Earlier identification, regulation of impurities in pharmaceutical products is critical throughout the medication development process because they have a high impact on drug quality, safety, and regulatory approval. Traditional analytical methods like LC-MS and NMR are frequently used, but they are labour intensive, time consuming and have limited capacity to detect unknown or trace level impurities. New opportunities to forecast impurity formation before experimental observation have been enabled by developments in cheminformatics and computer modelling. This study covers advanced chemical representation techniques, data generation, data curation, and model validation with highlighting recent advances in machine learning and deep learning algorithms for impurity prediction. In association with forecasting synthetic by products, degradation products, and harmful contaminants, traditional QSAR techniques, and contemporary deep learning models such as graph neural networks, transformer based architectures, and generative frameworks are examined. Additionally, discussed the increasing significance of explainable models for regulatory body acceptability. Lastly, newly developed advanced techniques like digital twins, automated impurity profiling, integrated reaction degradation modelling, and real-time monitoring are examined, demonstrating how computational methods are transforming impurity assessment from a reactive effort into a predictive and preventive procedure.

References

1. 1.Thombre, S., Bonde, C., Bhole, R., Gawad, J., & Karwa, P. (2026). Artificial intelligence in impurity prediction: current landscape, challenges, and future directions. Journal of Computer-Aided Molecular Design [DOI resolves to ACS Omega; bibliographic discrepancy noted]. https://doi.org/10.1021/ACSOMEGA.4C00565